Drug Benefit Defined By Dose-Response Relationships, CERTs Suggests
Executive Summary
Establishing the correct dose-response relationship for drugs is crucial to defining drug benefit, the Centers for Education & Research on Therapeutics suggested
You may also be interested in...
Rx Risk Descriptions Need To Be Standardized, FDA’s Galson Tells CERTs
The standardization of risk expressions to compare drugs would be a desirable risk management tool, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, suggested at a recent CERTs meeting
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials